Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Summary

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Timeline

Start

2023-04-19

Primary completion

2026-07-31

Completion

2026-10-31

Drugs

Indications